DTL, I have zero fear or doubt for the overall sector. I see those that position themselves best, exploding when the govt. releases their grip. People will continue to hesitate without full legalization. Once that happens, some of these companies will head north hard. That is why I am diversified in the sector. However, Green Cure has allowed a speck of uncertainty to set in for me with their stagnancy in using their media to advertise. It's a no brainer and it's not being used. That begs a question from me.
Do you have more than 14.4 or are you just putting it out there to create some sort of illusion, because you sure as heck aren't pushing it too hard.
If they have it, flaunt it. If they have it in reserve with a lot more, flaunt it even more and be redundant.
What are we seeing and hearing..... Crickets.
(0)
(0)
Green Cures & Botanical Distribution Inc. (GRCU) Stock Research Links
Elbit Systems Secures Major Contract for Defense Technology
Elbit Systems Ltd. (NASDAQ: ESLT) has recently made headlines as its shares see an increase following the announcement of a substantial $200 million contract. This contract, awarded by the Israeli Ministry of Defense, aims to bolster the country’s defense capabilities with advanced high-power laser systems.
A Breakthrough in Air Defense Systems
The contract is specifically aligned with the enhancement of the... Continue Reading
Airline Flight Suspensions Unfolding Across RegionsRecent escalations in Middle Eastern conflicts have sent shockwaves through international air travel, leading several airlines to either suspend flights to the region or reroute their operations to avoid conflict zones. The safety of travelers has become a prime concern, prompting heavy restrictions in flight schedules.Notable Airlines Cancelling FlightsBelow is a comprehensive overview of the airlines that have tempo... Continue Reading
Understanding Investment Dynamics: A Shift in FocusAs we dive into the financial landscape ahead of the next election, analysts at Citi are observing potential changes in investor behavior regarding the so-called ‘Trump trades.’ Although former President Donald Trump remains a popular figure in prediction markets, the enthusiasm for these trades seems to be reaching a crucial turning point.The Current Situation in Financial MarketsCurrently, the focus on Trump trades ... Continue Reading
Current Trends in US Earnings Season Highlighted by RBCThe latest quarterly earnings season for the S&P 500 has shown mixed results, according to insights provided by analysts at RBC Capital Markets.Performance AnalysisRBC's analysis indicates that around one-third of the way through the earnings reports, only 76% of companies have posted profits that exceed Wall Street's expectations. This is a decrease from the 80% performance seen in the previous quarter.... Continue Reading
JPMorgan Lowers Garmin's Price Target Amid Market Challenges
Recently, JPMorgan made headlines by adjusting its outlook on Garmin Ltd (NYSE: GRMN). The investment firm has lowered its price target for Garmin from $185 to $178, maintaining a Neutral rating on the stock. This revision reflects an ongoing examination of Garmin's performance as it navigates a complex market landscape.
While Garmin's shares have only dipped about 5% since the release of its second-quarter earnings ... Continue Reading
Introduction to PublicSquare's Recent DevelopmentsPublicSquare, officially known as PSQ Holdings, Inc. (NYSE: PSQH), has made notable strides in enhancing its financial technology landscape. Recently, the company announced a $5.35 million equity investment aimed at bolstering its payment platform, while also implementing significant cost-saving measures that included a staffing reduction of over 35%. This strategic initiative is set to streamline operations and ensure sustainable gro... Continue Reading
China's Economic Outlook for 2024
China's economic strategy for 2024 is centered on achieving a GDP growth rate of around 5%. This ambitious target has been articulated by China's Vice Minister of Finance, Liao Min, in recent discussions aimed at bolstering economic stability and growth. The commitment to this target reflects the proactive measures the government is willing to undertake to invigorate the national economy.
Fiscal Policies to Offset Economic Challenges
... Continue Reading
KalVista Pharmaceuticals and Their Promising Trials
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has made exciting strides with its investigational drug, sebetralstat, specifically for the treatment of hereditary angioedema (HAE). Presenting new data at a recent medical conference, KalVista showcased the positive outcomes from the Phase 3 KONFIDENT trial, which illuminated sebetralstat's potential as an effective oral treatment. The trial results suggest that early administration of... Continue Reading
Boeing's New Offerings for Common Stock and Depositary Shares
The Boeing Company (NYSE: BA) recently announced an exciting development in its financial strategy with the launch of concurrent public offerings of common stock and depositary shares. This move aims to strengthen the company's capital position and support its future growth initiatives.
Details of the Offerings
The company plans to offer 90 million shares of common stock, which have a par value of $5.00 per... Continue Reading
B. Riley Affirms Confidence in PennyMac Mortgage Investment Trust
Recently, B. Riley reaffirmed its Buy rating on PennyMac Mortgage Investment Trust (NYSE:PMT) with a stable price target of $16.00. This endorsement emerged after PennyMac's announcement of third-quarter financial outcomes for 2024 and subsequent adjustments to their financial model.
PennyMac reported a GAAP earnings per share (EPS) of $0.36 and a core EPS of $0.29 for the quarter, slightly lagging behind B. Ri... Continue Reading